HLA-DPB1 Antibody

中文名稱：

HLA-DPB1兔多克隆抗體
貨號：

CSB-PA14809A0Rb
規格：

￥440
圖片：
Western blot
All lanes: HLA-DPB1 antibody at 2µg/ml
Lane 1: sw1990 whole cell lysate
Lane 2: HGC27 whole cell lysate
Secondary
Goat polyclonal to rabbit IgG at 1/10000 dilution
Predicted band size: 30 kDa
Observed band size: 30 kDa

Immunohistochemistry of paraffin-embedded human tonsil tissue using CSB-PA14809A0Rb at dilution of 1:50
其他：

產品詳情
產品評價
相關產品
靶點詳情

產品詳情

產品名稱：

Rabbit anti-Homo sapiens (Human) HLA-DPB1 Polyclonal antibody
Uniprot No.：

P04440
基因名：

HLA-DPB1
別名：

beta1 domain MHC class II HLA DPB antibody; class II histocompatibility antigen; DP(W4) beta chain antibody; class II HLA beta chain antibody; DP beta 1 chain antibody; DP(W4) beta chain antibody; DPB1 antibody; DPB1_HUMAN antibody; HLA class II histocompatibility antigen antibody; HLA class II histocompatibility antigen; DP beta 1 chain antibody; HLA class II histocompatibility antigen; DP(W4) beta chain antibody; HLA DP14-beta chain antibody; HLA-DP antibody; HLA-DP histocompatibility type; beta-1 subunit antibody; HLA-DP1B antibody; HLA-DPB antibody; HLA-DPB1 antibody; major histocompatibility complex class II antigen beta chain antibody; major histocompatibility complex; class II; DP beta 1 antibody; MHC class II antigen beta chain antibody; MHC class II antigen DP beta 1 chain antibody; MHC class II antigen DPB1 antibody; MHC class II antigen DPbeta1 antibody; MHC class II HLA-DP-beta-1 antibody; MHC class II HLA-DRB1 antibody; MHC HLA DPB1 antibody
宿主：

Rabbit
反應種屬：

Human
免疫原：

Recombinant Human HLA class II histocompatibility antigen, DP beta 1 chain protein (30-225AA)
免疫原種屬：

Homo sapiens (Human)

標記方式：

Non-conjugated

本頁面中的產品，HLA-DPB1 Antibody (CSB-PA14809A0Rb)，的標記方式是Non-conjugated。對于HLA-DPB1 Antibody，我們還提供其他標記。見下表：

標記方式	貨號	產品名稱	應用
HRP	CSB-PA14809B0Rb	HLA-DPB1 Antibody, HRP conjugated	ELISA
FITC	CSB-PA14809C0Rb	HLA-DPB1 Antibody, FITC conjugated
Biotin	CSB-PA14809D0Rb	HLA-DPB1 Antibody, Biotin conjugated	ELISA

克隆類型：

Polyclonal
抗體亞型：

IgG
純化方式：

>95%, Protein G purified
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, PH 7.4
產品提供形式：

Liquid
應用范圍：

ELISA, WB, IHC

推薦稀釋比：

Application	Recommended Dilution
WB	1:1000-1:5000
IHC	1:20-1:200

Protocols：

ELISA Protocol
Western Blotting (WB) Protocol
Immunohistochemistry (IHC) Protocol
儲存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產品評價

靶點詳情

功能：

Binds peptides derived from antigens that access the endocytic route of antigen presenting cells (APC) and presents them on the cell surface for recognition by the CD4 T-cells. The peptide binding cleft accommodates peptides of 10-30 residues. The peptides presented by MHC class II molecules are generated mostly by degradation of proteins that access the endocytic route, where they are processed by lysosomal proteases and other hydrolases. Exogenous antigens that have been endocytosed by the APC are thus readily available for presentation via MHC II molecules, and for this reason this antigen presentation pathway is usually referred to as exogenous. As membrane proteins on their way to degradation in lysosomes as part of their normal turn-over are also contained in the endosomal/lysosomal compartments, exogenous antigens must compete with those derived from endogenous components. Autophagy is also a source of endogenous peptides, autophagosomes constitutively fuse with MHC class II loading compartments. In addition to APCs, other cells of the gastrointestinal tract, such as epithelial cells, express MHC class II molecules and CD74 and act as APCs, which is an unusual trait of the GI tract. To produce a MHC class II molecule that presents an antigen, three MHC class II molecules (heterodimers of an alpha and a beta chain) associate with a CD74 trimer in the ER to form a heterononamer. Soon after the entry of this complex into the endosomal/lysosomal system where antigen processing occurs, CD74 undergoes a sequential degradation by various proteases, including CTSS and CTSL, leaving a small fragment termed CLIP (class-II-associated invariant chain peptide). The removal of CLIP is facilitated by HLA-DM via direct binding to the alpha-beta-CLIP complex so that CLIP is released. HLA-DM stabilizes MHC class II molecules until primary high affinity antigenic peptides are bound. The MHC II molecule bound to a peptide is then transported to the cell membrane surface. In B-cells, the interaction between HLA-DM and MHC class II molecules is regulated by HLA-DO. Primary dendritic cells (DCs) also to express HLA-DO. Lysosomal microenvironment has been implicated in the regulation of antigen loading into MHC II molecules, increased acidification produces increased proteolysis and efficient peptide loading.
基因功能參考文獻：
1. Data suggest that HLA-DP molecules with beta-chains encoding Gly84 (DP(84Gly)) uses both class I and II antigen-processing pathways to present peptides derived from intracellular and extracellular sources. PMID: 28489076
2. HLA-DP polymorphisms (rs3077 and rs9277535) were associated with Systemic lupus erythematosus susceptibility in a Chinese population PMID: 28094303
3. High frequency expression of DPB1*0401 and *0601 are significantly associated with susceptibility to rheumatoid arthritis, it may be a risk factor for occurrence of rheumatoid arthritis. Low frequency expression of DPB1*0101, *0402 and *0501 may be negatively associated with rheumatoid arthritis, it may be a protective factor for occurrence of rheumatoid arthritis. PMID: 29425827
4. The rs3117242 of HLA-DPB1 could be considered a genetic risk factor for granulomatosis with polyangiitis in Chinese Han people. PMID: 26014903
5. HLA-DPB1*05:01 gene was associated with the geographical region of PV and the BTNL2 gene was significantly associated with family history and age of onset of PV. In conclusion, the HLA-DPB1*05:01 and BTNL2 genes might be responsible for the complicacy of clinical features. PMID: 28581127
6. In this single-center study, HLA-DPB1 matching influenced outcomes of patients undergoing ASCT for hematologic malignancy. PMID: 28632323
7. HLA-DPB1*15:01 allele was more frequent in the spontaneous seroconverted control group compared to Chronic hepatitis B Turkish patients. PMID: 29560661
8. Genotyping and expression analysis in HLA class II gene revealed that two single nucleotide polymorphisms of HLA-DPB1 (rs2071025 and rs3116996) were significantly correlated to RNA expression and progression of hepatitis C virus-related liver diseases. PMID: 28332201
9. Amino acid changes in the allergen-binding pocket of HLA-DPbeta1 are likely to influence pollinosis/sensitization to the allergenic peptide of JC pollen and determine the pollinosis risk for each individual exposed to JC pollen. PMID: 28460831
10. The results showed that rs9277535 HLA-DPB1 allele frequency is associated with chronic hepatitis B infection in the Turkish patients. PMID: 28119119
11. report contributes to emerging data showing clinical significance of the HLA-DP region genetic markers beyond structural matching of DPB1 alleles. PMID: 27595289
12. The HLA-DP rs9277535 variant genotypes were directly associated with hepatitis B virus persistence compared to healthy controls. PMID: 27291710
13. No statistically significant association was found between rs9277535 SNP and chronic hepatitis B. PMID: 28613373
14. Two new signals were observed at genome-wide significance (P < 5 x 10-8), namely, rs7216064 (17q24.3, BPTF), for overall lung adenocarcinoma risk, and rs3817963 (6p21.3, BTNL2) which is specific to cases with EGFR mutations. In further sub-analyses by EGFR status, rs9387478 (ROS1/DCBLD1) and rs2179920 (HLA-DPB1) showed stronger estimated associations in EGFR-positive compared to EGFR-negative cases PMID: 28025329
15. we show strong immunogenicity of HLA-DPB1 mismatch alleles in CD45RA-selected CD4 T cells of stem-cell donors and introduce a novel strategy to reliably generate HLA-DPB1-specific CD4 CTL that might be powerful cellular therapeutics in relapsed or refractory AML after HSCT. PMID: 27479183
16. There was no increased risk of rheumatoid arthritis in mothers of children with phenylalanine at position 9 of DPB1. PMID: 28391248
17. rs141530233 and rs1042169 at the HLA-DPB1 locus are associated with ANCA-associated vasculitis risk. PMID: 28029757
18. Seven nonconservative AA substitutions in peptide-binding positions had a significantly stronger impact on DeltaFD compared with 5 others (P = .0025), demonstrating qualitative differences in the relative impact of AA polymorphism in HLA-DPB1. PMID: 27162243
19. Study showed that HLA-DQ (rs7453920) was associated with prognosis of liver transplant recipients. The A allele of rs7453920 served as a protective factor in liver function recovery. HLA-DP (rs3077 and rs9277535) did not show any correlation with the hepatitis B virus infection and prognosis. PMID: 28640108
20. two dermatomyositis susceptibility loci at 7q34 and 10q24.2 PMID: 27153935
21. this study shows that HLA-DP gene polymorphisms are associated with ankylosing spondylitis in Southwest China PMID: 27394003
22. DRB1*13:02 (P = 0.0011, Pc = 0.0319, odds ratio [OR] 0.46, 95% confidence interval [CI] 0.29-0.73), DRB1*14:06 (P = 6.60X10-5, Pc = 0.0020, OR 0.05, 95%CI 0.01-0.41), DQB1*03:01 (P = 0.0009, Pc = 0.0150, OR 0.56, 95%CI 0.40-0.79), and DPB1*02:01 (P = 5.16X10-6, Pc = 8.77X10-5, OR 0.52, 95%CI 0.39-0.69) were protectively associated with Systemic Sclerosis in Japanese. PMID: 27116456
23. The HLA-DPB1*04:01:01G allele was significantly more frequent among women diagnosed with severe preeclampsia/eclampsia compared with controls. PMID: 27121092
24. the HLA-DP/DQ clusters contribute independently to HBV infection, and the 3'-UTR region of HLA-DPB1 represents an important functional region involved in HBV infection PMID: 26197724
25. Significant associations between chronic hepatitis B infection and five DPB1 alleles (two susceptibility alleles, DPB1(*) 05:01 and (*) 09:01, and three protective alleles, DPB1(*) 02:01, (*) 04:01, and (*) 04:02) were confirmed in Japanese individuals. PMID: 26449183
26. The observed positive association between integrated HIV-1 DNA load and frequency of CD8(+)DR/DP/DQ(+) cells indicates that a close correlation between HIV persistence and immune activation continues during consistently suppressive therapy. PMID: 26498496
27. Our results further confirm that genetic variants in the HLA-DP locus are strongly associated with reduced HBV infection and increased the likelihood of spontaneous viral clearance. PMID: 26462556
28. Thyroid autoimmunity is highly prevalent in type 1 diabetes mellitus patients and the risk is modulated by HLA-DRB1 and HLA-DPB1 loci. PMID: 26405068
29. DQB1*06 and DPB1*13 have roles in modulating vaccine-induced antibody responses to affect HIV-1 acquisition PMID: 26180102
30. rs9277535 in HLA-DPB1 is a significantly associated SNP associated with chronic hepatitis B virus infection and viral clearance. PMID: 24846544
31. Cellular misfolded proteins rescued from degradation by MHC class II molecules seem to be involved in autoimmune diseases as a target for autoantibodies. (review) PMID: 26915265
32. findings indicate the HLA-DPB1*13:01 and +550 A alleles are significantly associated with cervical squamous cell carcinoma (CSCC) risk in Taiwanese women; in addition, significant increase in CSCC risk was observed for HLA-DPB1*13:01-G and DPB1*02:01-A haplotypes PMID: 26031576
33. There was a significant linkage disequilibrium between these HLA-DP candidate SNPs and HLA-DPB1 protective alleles PMID: 25389088
34. This implies the potential of rs3128965 of HLA-DPB1 as a genetic marker for diagnosis and prediction of the AERD phenotype. PMID: 25536158
35. HLA-DPB1*04:01 may reduce the risk of tissue transglutaminase autoantibodies, an early marker of celiac disease, among DR3-DQ2 children, confirming that additional variants in the HLA region influence the risk for celiac disease autoimmunity. PMID: 26010309
36. Among recipients of HLA-DPB1-mismatched transplants from donors with the low-expression allele, recipients with the high-expression allele had a high risk of GVHD. PMID: 26267621
37. Results identified new susceptibility variants to narcolepsy in HLA-DPB1 and HLA-DQB1 loci in Japanese patients. PMID: 25256355
38. The affinities of peptides for Beryllium loaded HLA-DP2 were found to depend of their amino acid composition and the peptides carrying acidic group at positions 4 and 7 are among the strongest binders. PMID: 25369028
39. Polymorphisms in HLA-DPB1 are strongly associated with interindividual differences in neutralizing antibody levels to rubella vaccination. PMID: 25293367
40. This is the first report of the association between early Crohn's disease and the HLA DRB1*501 single nucleotide polymorphisms. PMID: 25664710
41. No increase in sarcoidosis was seen with either Glu69 or beryllium exposure. In Glu69 positive men with exposure >/=10 years, the trend towards increasing rate of COPD was reversed; a significant interaction of duration of exposure and Glu69 was detected. PMID: 25305207
42. Data indicate that thirty eight HLA-DPB1 alleles were found in the systemic scleroderma cohort. PMID: 24498086
43. HLA-DPB1 alleles influence the kinetics of anti-hepatitis B antibodies in hepatitis B booster recipients. PMID: 24285177
44. Data indicate that HLA-DP2 transgenic mice developed a beryllium-specific adaptive immune response composed of CD4+ T cells. PMID: 24912188
45. Data indicate five members of of DPbeta chains containing Lys-69 and GGPM 84-87, which assemble with DRalpha. PMID: 24214983
46. Our results demonstrated that the rs3077 and rs9277535 HLA-DP polymorphisms reduced hepatitis B virus infection and increased the likelihood of spontaneous viral clearance in some Asian populations. PMID: 23601003
47. Studied three HLA-DP and IL28B SNPs of CHB patients with and without spontaneous HBsAg seroclearance. Haplotype analysis of HLA-DP polymorphisms showed association with HBsAg seroclearance. PMID: 23449268
48. HLA-DRB1*04:01 and HLA-DPB1*04:01 alleles were detected at higher frequencies in influenza-seroprotected compared with non-seroprotected individuals. PMID: 23951151
49. The conditional logistic regression tests showed that DPB1*04:01 is independently associated with non-obstructive azoospermia(NOA), confirming the involvement of the HLA region in the etiology of NOA in Japanese patients. PMID: 23934009
50. We identified the SEMA6A and HLA-DP loci as significant contributors to risk for granulomatosis with polyangiitis, with the HLA-DPB1*04 allele almost completely accounting for the MHC association PMID: 23740775
顯示更多

收起更多
亞細胞定位：

Cell membrane; Single-pass type I membrane protein. Endoplasmic reticulum membrane; Single-pass type I membrane protein. Golgi apparatus, trans-Golgi network membrane; Single-pass type I membrane protein. Endosome membrane; Single-pass type I membrane protein. Lysosome membrane; Single-pass type I membrane protein. Note=The MHC class II complex transits through a number of intracellular compartments in the endocytic pathway until it reaches the cell membrane for antigen presentation.
蛋白家族：

MHC class II family
數據庫鏈接：

HGNC: 4940

OMIM: 142858

KEGG: hsa:3115

STRING: 9606.ENSP00000408146

UniGene: Hs.485130

Most popular with customers

YWHAG Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
YWHAB Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF, FC

Species Reactivity: Human, Mouse, Rat
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
XRCC5 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF

Species Reactivity: Human
XPNPEP1 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
XDH Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WT1 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WFDC2 Recombinant Monoclonal Antibody

Applications: ELISA, WB, FC

Species Reactivity: Human